Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
RICHARD CHILDS · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2020 · $3,038,595 — Approximately 20 years ago, we initiated the first ever clinical trail investigating allogeneic stem cell transplantation in patients with treatment refractory metastatic renal cell carcinoma (RCC). Definitive evidence for an allogeneic graft-versus-RCC effect has been demonstrated with complete reg…
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,847,416 — Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldwide. Intradermal (ID) vaccination with BCG has variable efficacy against pulmonary tuberculosis, the major cause of mortality and disease transmission. We showed that the route and dose of BCG vaccination alters circ…
Julie E. Ledgerwood · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $592,800 — The evaluation of a vaccine candidate targeting COVID-19 and collection of samples to support translational immunology research support the broader VRC mission. For this project, sample collection was conducted under the VRC 200 protocol while the evaluation of an investigational vaccine candidate …
Katrin Mayer-Barber · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,293,685 — The development of effective vaccines and host directed therapies (HDT) against M. tuberculosis (Mtb) infection requires a detailed understanding of the cellular basis of protective immunity. Considerable progress has been made in our understanding of protective adaptive immunity, yet relatively lit…
Nir Hacohen · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $230,484 — Project Summary The overall objective of the U19 is to discover the role of the PD-1 pathway in human immunity by studying the effects of therapeutic PD-1 blockade on immune responses to chronic viruses (Project 1) and preventive vaccines (Project 2). To monitor adaptive immune responses in patients…
Kai W Wucherpfennig · BRIGHAM AND WOMEN'S HOSPITAL · 2020 · $398,683 — Abstract T cells are central effector cells of protective anti-tumor immunity, but little is currently known about these important immune cells in human GBM. We have generated single-cell RNA-seq data on tumor-infiltrating T cell populations from GBM patients at initial diagnosis or relapse. We used…
JOHN D. AITCHISON · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $451,361 — PROJECT SUMMARY (Core C - Gene Expression Signatures) HIV has proven its ability to defeat all vaccine candidates tested to date. However, evidence in humans and model systems demonstrates that immune system is capable of generating antibodies that neutralize multiple HIV-1 viral strains. While t…
MICHAEL D GUNN · DUKE UNIVERSITY · 2020 · $160,934 — Historically, stimulation of humoral immunity in the form of antibodies has been the most effective means to provide protection against most viral infections. For this reason, almost all SARS-CoV-2 vaccine efforts are focused on stimulating humoral immunity. At the same time, there is evidence to su…
Paola Massari · TUFTS UNIVERSITY BOSTON · 2019 · $247,500 — Project Summary Neisseria gonorrhoeae reproductive tract infections can lead to chronic and severe consequences in women, where diagnosis is frequently delayed by lack of symptoms, contrary to male infections. A once-simple antibiotic treatment gonococcal infection is now compromised by a worldwide …
Brian Geiss · COLORADO STATE UNIVERSITY · 2019 · $374,993 — Approximately 2/3rd of the world population is at risk of infection by at least one of the 35 insect-borne flaviviruses known to cause disease in humans. There are currently few vaccines and no therapeutics available to treat patients infected by flaviviruses such as Dengue, Zika, and West Nile viru…
Michael Gerner · UNIVERSITY OF WASHINGTON · 2019 · $524,320 — The innate and adaptive arms of the immune system are integrally linked, with dendritic cells (DCs), innate antigen presenting cells, providing critical instructions to elicit the generation of adaptive T cell immunity. Using a novel analytical imaging approach, we recently uncovered that different …
Jesse Hong-Sae Erasmus · ACCESS TO ADVANCED HEALTH INSTITUTE · 2019 · $61,610 — PROJECT SUMMARY Viral replicons, or self-replicating RNA elements incapable of initiating a spreading infection, are traditionally packaged into virus particles, termed viral replicon particles (VRPs), for in vivo delivery. Alternatively, they can be encoded on a plasmid DNA and transfected for host…
Steven Edward Bosinger · EMORY UNIVERSITY · 2019 · $379,584 — DESCRIPTION (provided by applicant): In the vast majority of vaccine trials, the primary readouts are empirical do not collect information about the immunological determinants of a vaccine's success or failure. In recent years, several vaccine studies have combined high-throughput transcriptomi…
Susan Leilani Fink · UNIVERSITY OF WASHINGTON · 2019 · $233,250 — Project Summary Zika virus (ZIKV) is a recently recognized global health threat due to the wide geographic distribution of risk and potential for severe consequences of infection. There remains no antiviral in clinical use for ZIKV, or any flavivirus, and many unanswered questions regarding the basi…
Alison Whitney Ashbrook · ROCKEFELLER UNIVERSITY · 2019 · $63,746 — PROJECT SUMMARY/ABSTRACT Translation is a critical stage at which the abundance, timing, and localization of gene expression is regulated. In the case of infection, precise control of translational machinery and processes can determine whether an effective antiviral program is initiated or whether …
Antonella Casola · UNIVERSITY OF TEXAS MED BR GALVESTON · 2019 · $237,000 — PROJECT SUMMARY/ABSTRACT Acute respiratory tract infections are a leading cause of morbidity and mortality in children worldwide. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children, elderly and in immunocompromised patients, as well as of asthma exac…
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $3,659,615 — While HIV-1 broadly neutralizing antibodies (bnAbs) provide potent protection from HIV-1, to date they have been difficult to induce in the setting of vaccination. A second type of HIV-1 envelope (Env) antibodies that are easy to induce are termed non-neutralizing antibodies (NNAbs) (because they ar…
Rachel Fearns · BOSTON UNIVERSITY MEDICAL CAMPUS · 2019 · $529,282 — Marburg virus (MARV) belongs to the filovirus family and is highly pathogenic in humans. Despite being classified as Category A Priority Pathogen by NIAID, and its potential to cause large-scale outbreaks, similar to the recent Ebola virus outbreak, research on MARV lags significantly behind that on…
Isaac Jonathan Krauss · BRANDEIS UNIVERSITY · 2019 · $124,644 — Project Summary/Abstract An estimated 2.3 billion people live at risk of infection by the Zika virus (ZIKV), a mosquito-borne flavivirus that causes microcephaly in newborns, as well as eye- and neurological defects, and Guillain-Barre syndrome in adults. Zika co-circulates in the same geographical …
HOMAYON GHIASI · CEDARS-SINAI MEDICAL CENTER · 2019 · $472,500 — Project Summary Following ocular primary herpes simplex virus type-1 (HSV-1) infection, the virus replicates in the eye and establishes latency in the trigeminal ganglia (TG). In a latently infected individual, the virus can occasionally reactivate and travel back to the eye causing recurrent disea…